The HDAC6 Knockout NCI-H1703 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the NCI-H1703 human lung squamous cell carcinoma line, featuring targeted disruption of the HDAC6 gene. This polyclonal knockout model is designed to ablate the cytoplasmic deacetylase activity of HDAC6, enabling investigation of its roles in autophagy, aggresome formation, and cell motility. The gene editing approach generates a heterogeneous pool of cells with loss-of-function alleles, providing a robust system for functional studies without clonal selection artifacts.
The NCI-H1703 host cell line is an adherent epithelial cell line established from a male patient with lung squamous cell carcinoma, a major subtype of non-small cell lung cancer. This line is widely utilized for studying oncogenic signaling pathways, drug resistance, and tumor cell biology relevant to squamous lung carcinoma. Its well-characterized growth properties and genetic background make it a suitable platform for evaluating the impact of HDAC6 loss in a disease-relevant cellular context.
HDAC6 is a predominantly cytoplasmic class IIb deacetylase that uniquely targets non-histone substrates, including ??-tubulin at Lys40, Hsp90, and cortactin. Through deacetylation of ??-tubulin, HDAC6 modulates microtubule dynamics and stability, influencing cell migration and intracellular transport. It is critically involved in aggresome formation by binding ubiquitinated proteins and interacting with dynein and p62/SQSTM1 to transport misfolded protein aggregates to the microtubule-organizing center for degradation. HDAC6 is regulated by various upstream signals such as EGFR, Aurora A kinase, GSK3??, and TGF-??, and its activity affects downstream pathways including Hsp90 chaperone function, autophagy flux, and EGFR trafficking. Consequently, HDAC6 integrates proteotoxic stress responses with cell motility and receptor signaling.
In the context of NCI-H1703 lung cancer cells, HDAC6 knockout abolishes cytoplasmic deacetylation of ??-tubulin, leading to hyperacetylated, stabilized microtubules. This disrupts aggresome formation and impairs autophagy-mediated clearance of ubiquitinated proteins, resulting in accumulation of protein aggregates. The loss of HDAC6 function reduces cell migration, heightens sensitivity to proteasome inhibitors such as bortezomib, and alters EGFR and TGF-?? signaling cascades. These phenotypic changes highlight HDAC6 as a potential therapeutic target in squamous cell carcinoma, where aberrant autophagy and enhanced motility contribute to tumor progression and drug resistance.
This polyclonal HDAC6 knockout product supports a wide array of research applications, including mechanistic studies of autophagy and aggresome biology in lung cancer, screening for selective HDAC6 inhibitors, and evaluating combination therapies with proteasome inhibitors or EGFR inhibitors. Common assays include Western blotting for HDAC6 and acetyl-??-tubulin, immunofluorescence for acetylated tubulin and aggresomes, cell migration and invasion assays, and autophagy flux analysis via LC3 turnover and p62 degradation. The cells also facilitate drug sensitivity profiling, apoptosis assays, and biomarker discovery. For further details, please contact Ascent Research.
